Drugs · acquisition-cost intelligence
loteprednol etabonate
· ingredient loteprednol etabonate· LOTEPREDNOL ETABONATE 5 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$18.77
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other loteprednol etabonate products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| LOTEMAX | $14.49 | −$4.28 |
| loteprednol etabonate | $30.46 | +$11.69 |
| Lotemax SM | $49.48 | +$30.71 |
| Alrex | $57.93 | +$39.15 |
| Lotemax | $99.75 | +$80.97 |
| Inveltys | $103.17 | +$84.40 |
Medicare Part D coverage · CY2026
On 170 plan formularies · typical tier 4
Prior auth 0% · Step therapy 1% · Quantity limit 31% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.